Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme

BACKGROUND: Mepolizumab was available in France as part of an early access programme for patients with severe eosinophilic asthma (nominative autorisation temporaire d'utilisation [temporary use authorisation] (nATU)) before its commercialisation. This study aimed to characterise patients who r...

Descripción completa

Detalles Bibliográficos
Autores principales: Taillé, Camille, Chanez, Pascal, Devouassoux, Gilles, Didier, Alain, Pison, Christophe, Garcia, Gilles, Charriot, Jeremy, Bouée, Stéphane, Gruber, Alina, Pribil, Celine, Bourdin, Arnaud, Humbert, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315004/
https://www.ncbi.nlm.nih.gov/pubmed/32241829
http://dx.doi.org/10.1183/13993003.02345-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315004/
https://www.ncbi.nlm.nih.gov/pubmed/32241829
http://dx.doi.org/10.1183/13993003.02345-2019

Ejemplares similares